J.W.R has served on Takeda Specialist/Advisory Boards. mutant cell lines and demonstrate sustained tumor growth inhibition of EGFR-mutant tumor xenograft harboring probably the most common Ex lover20Ins resistance to the currently authorized first-line EGFR-tyrosine kinase inhibitors (TKI), erlotinib, gefitinib and afatinib (2,4C8). The rare A763_Y764insFQEA mutation (6% prevalence across the Ex lover20Ins section) is the … Continue reading J